AIM ImmunoTech Advances Ampligen Toward Phase 3 Cancer Trial
OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...
Imfinzi
Advertisement
CervoMed Secures UK ILAP Innovation Passport for Neflamapimod
BOSTON, Aug. 4, 2026 CervoMed Inc. announced that its investigational oral therapy neflamapimod has been granted an Innovation Passport...
AIM ImmunoTech Advances DURIPANC Trial with Final Dosing Milestone
OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...
AIM ImmunoTech Advances Ampligen Toward Potential Pivotal Development
OCALA, Fla., June 24, 2026 AIM ImmunoTech Inc. highlighted significant progress across its pancreatic cancer development program, positioning Ampligen®...
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment
Ocala, Florida | June 18, 2026 AIM ImmunoTech Inc. announced that the final patient has received the first dose...
Advertisements
Merck Animal Health Acquires TARGAN to Advance Poultry Technology
RAHWAY, N.J., June 11, 2026 Merck Animal Health, a division of Merck & Co., Inc., has signed a definitive...
Roche Expands VENTANA MMR Companion Diagnostic Across Multiple Cancer Types
TUCSON, Arizona, USA, June 11, 2026 Roche Diagnostics has announced a significant expansion of its precision oncology diagnostics portfolio...
AstraZeneca’s Imfinzi Wins FDA Approval in NMIBC
CAMBRIDGE, United Kingdom, May 28, 2026 AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S....
AstraZeneca Unveils Major ASCO 2026 Cancer and Rare Disease Data
CAMBRIDGE, UK, 22 May 2026 AstraZeneca announced a major scientific showcase at the upcoming ASCO Annual Meeting 2026, highlighting...
AstraZeneca VOLGA Trial Boosts Bladder Cancer Survival
CAMBRIDGE, UK, May 14, 2026 AstraZeneca announced positive interim results from the global Phase III VOLGA trial, demonstrating that...
Advertisement
